JP2021522269A5 - - Google Patents

Info

Publication number
JP2021522269A5
JP2021522269A5 JP2020560257A JP2020560257A JP2021522269A5 JP 2021522269 A5 JP2021522269 A5 JP 2021522269A5 JP 2020560257 A JP2020560257 A JP 2020560257A JP 2020560257 A JP2020560257 A JP 2020560257A JP 2021522269 A5 JP2021522269 A5 JP 2021522269A5
Authority
JP
Japan
Prior art keywords
optionally substituted
integrin
group
cargo molecule
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560257A
Other languages
English (en)
Japanese (ja)
Other versions
JP7704529B2 (ja
JP2021522269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/029393 external-priority patent/WO2019210200A1/en
Publication of JP2021522269A publication Critical patent/JP2021522269A/ja
Publication of JP2021522269A5 publication Critical patent/JP2021522269A5/ja
Priority to JP2024232254A priority Critical patent/JP2025060958A/ja
Application granted granted Critical
Publication of JP7704529B2 publication Critical patent/JP7704529B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560257A 2018-04-27 2019-04-26 インテグリン標的化リガンドとその使用 Active JP7704529B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024232254A JP2025060958A (ja) 2018-04-27 2024-12-27 インテグリン標的化リガンドとその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862663763P 2018-04-27 2018-04-27
US62/663,763 2018-04-27
US201962790372P 2019-01-09 2019-01-09
US62/790,372 2019-01-09
PCT/US2019/029393 WO2019210200A1 (en) 2018-04-27 2019-04-26 Integrin targeting ligands and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024232254A Division JP2025060958A (ja) 2018-04-27 2024-12-27 インテグリン標的化リガンドとその使用

Publications (3)

Publication Number Publication Date
JP2021522269A JP2021522269A (ja) 2021-08-30
JP2021522269A5 true JP2021522269A5 (https=) 2022-06-14
JP7704529B2 JP7704529B2 (ja) 2025-07-08

Family

ID=68294255

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560257A Active JP7704529B2 (ja) 2018-04-27 2019-04-26 インテグリン標的化リガンドとその使用
JP2024232254A Pending JP2025060958A (ja) 2018-04-27 2024-12-27 インテグリン標的化リガンドとその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024232254A Pending JP2025060958A (ja) 2018-04-27 2024-12-27 インテグリン標的化リガンドとその使用

Country Status (20)

Country Link
US (1) US20210093725A1 (https=)
EP (2) EP3784269B1 (https=)
JP (2) JP7704529B2 (https=)
KR (1) KR102787533B1 (https=)
CN (2) CN118994152A (https=)
AU (1) AU2019260738B2 (https=)
BR (1) BR112020021949A2 (https=)
CA (1) CA3097656A1 (https=)
DK (1) DK3784269T3 (https=)
ES (1) ES2983950T3 (https=)
FI (1) FI3784269T3 (https=)
HR (1) HRP20240907T1 (https=)
IL (2) IL309955A (https=)
JO (1) JOP20200266A1 (https=)
MX (1) MX2020011290A (https=)
SA (1) SA520420426B1 (https=)
SG (1) SG11202009734VA (https=)
SI (1) SI3784269T1 (https=)
TW (1) TW202014206A (https=)
WO (1) WO2019210200A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202009734VA (en) * 2018-04-27 2020-11-27 Arrowhead Pharmaceuticals Inc Integrin targeting ligands and uses thereof
SG11202105577TA (en) 2019-01-09 2021-06-29 Arrowhead Pharmaceuticals Inc Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
CA3189065A1 (en) * 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
WO2023283595A2 (en) * 2021-07-07 2023-01-12 Alnylam Pharmaceuticals, Inc. Integrin targeting ligands for ocular delivery of rnai compounds
CN121399119A (zh) * 2023-06-19 2026-01-23 广东众生睿创生物科技有限公司 一种整合素配体及其用途
WO2025252118A1 (zh) * 2024-06-06 2025-12-11 苏州瑞博生物技术股份有限公司 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途
WO2025261536A1 (zh) * 2024-06-21 2025-12-26 长春金赛药业有限责任公司 一种整联蛋白配体关键中间体及其制备方法
WO2026034639A1 (ja) * 2024-08-09 2026-02-12 株式会社Spin Wave ペプチド合成用可溶性担体およびこれを用いた合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR20010033248A (ko) 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
CN102026671B (zh) * 2008-03-14 2014-09-03 Visen医药公司 整联蛋白靶向试剂及使用其的体内和体外成像方法
WO2013110578A1 (en) * 2012-01-27 2013-08-01 F. Hoffmann-La Roche Ag Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3
AU2014209853B2 (en) * 2013-01-28 2017-12-21 Janssen Sciences Ireland Uc Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents
CN105247051A (zh) 2013-02-28 2016-01-13 箭头研究公司 治疗epas1相关疾病的有机组合物
WO2015021092A1 (en) 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
US11971402B2 (en) * 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
BR112017023432A2 (pt) * 2015-04-30 2018-07-24 Scifluor Life Sciences Inc Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
AR104754A1 (es) 2015-05-29 2017-08-09 Arrowhead Pharmaceuticals Inc Agentes de unión de tetrapéptido escindibles biológicamente
SG11202009734VA (en) * 2018-04-27 2020-11-27 Arrowhead Pharmaceuticals Inc Integrin targeting ligands and uses thereof

Similar Documents

Publication Publication Date Title
JP2021522269A5 (https=)
JP6932389B2 (ja) 標的化コンジュゲートならびにその粒子及び製剤
JP5960890B2 (ja) 担体ナノ粒子ならびに関連する組成物、方法およびシステム
JP2021050212A (ja) 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
JP2023541427A (ja) 骨格筋送達プラットフォーム及び使用方法
JP2021501754A5 (https=)
US20160193354A1 (en) Antisense oligonucleotides with improved pharmacokinetic properties
Fuentes-Paniagua et al. Thiol-ene synthesis of cationic carbosilane dendrons: a new family of synthons
EA014097B1 (ru) ОЛИГОНУКЛЕОТИДЫ ЗАМКНУТОЙ НУКЛЕИНОВОЙ КИСЛОТЫ (LNA) ДЛЯ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ HIF-1a И ИХ ПРИМЕНЕНИЕ
KR20150100706A (ko) 입자 내에 캡슐화된 표적화된 콘쥬게이트 및 이의 제형
UA125655C2 (uk) Терапевтичні дендримери
JP2011514423A (ja) 生分解性架橋分枝状ポリ(アルキレンイミン)
CN105007905A (zh) 靶向纳米粒子
CN116348150A (zh) 用于递送治疗剂的脂质缀合物
JP6316209B2 (ja) αVβ3を発現する細胞への標的化送達のためのインテグリンアンタゴニスト結合体
US20240050463A1 (en) Therapeutic compositions and methods for treating hepatitis b
AU2024291722A1 (en) Targeted chemical drug and preparation method therefor, pharmaceutical composition, and use of targeted chemical drug
US20130011448A1 (en) System for improved delivery of gene modulating compounds
US20130079383A1 (en) Lipid Compounds Targeting VLA-4
JP2001515060A (ja) 新リポポリアミン、その調製および適用
DK2806897T3 (en) INTEGRIN ANAGONIST CONJUGATES FOR TARGETED RELEASE TO LFA-1 EXPRESSING CELLS
MX2014008403A (es) Conjugados de antagonista de la integrina para su suministro dirigido a celulas que expresan vla-4.
US20200046846A1 (en) Modified oligonucleotides and therapeutic uses thereof
US9447035B2 (en) Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
HK1202426B (en) Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3